Endocrine Abstracts

Background: Polycystic ovary syndrome (PCOS) is common with a suggested prevalence of 6–7% in Caucasian women of reproductive age. The presence of cardiovascular risk factors of obesity, insulin resistance and dyslipidaemia may predispose women with PCOS to coronary heart disease, although this remains controversial. This study aimed to contrast and compare the changes in lipid profile and hs-CRP following treatment with metformin, orlistat and pioglitazone in women with ...

Background: PCOS is associated with a clustering of cardiovascular risk factors. Increased serum levels of vascular endothelial growth factor (VEGF) are thought to be proatherogenic, and have also been found to be elevated in PCOS. This study was undertaken to determine the changes of VEGF in patients with PCOS after rimonabant and/or metformin intervention.Methods: A 6-month randomised open labelled parallel study of rimonabant or metformin in 20 patien...

Introduction: Polycystic ovary syndrome (PCOS) has shown to be associated with increased levels of pro-inflammatory cytokines. This study was undertaken to determine the changes of pro-inflammatory cytokines in patients with PCOS after rimonabant and/or metformin treatment.Methods: A 3 month randomised open labelled parallel study of rimonabant or metformin in 20 patients with PCOS with a body mass index >30 kg/m2 was undertaken. Subsequen...

Objective: We aim to study whether a difference exists in cardiovascular risk and variability of IR within the hyperandrogenic group of women with PCOS who are ovulatory and anovulatory.Method: Fifty-three women with PCOS were recruited. All subjects were diagnosed to have PCOS by the ESHRE/ASRM Rotterdam criteria where all patients had evidence of biochemical hyperandrogenism and hirsutism, chronic anovulation and polycystic ovaries on transvaginal ultr...

Objective: Androsterone glucuronide (ADTG) concentrations have been suggested as a more reliable marker of the effects of androgen at the target tissue level and is significantly elevated in hirsute compared to non-hirsute women with PCOS. As the mechanism for hyperandrogenemia in obese and nonobese PCOS may differ, this study compares the different precursors of testosterone, including DHEAS, ADTG and androstenedione in nonobese compared to obese women with PCOS and their imp...

Context: Weight loss and metformin therapy are beneficial in improving the hormonal and metabolic consequences of PCOS. Rimonabant has been found to reduce weight and improve the metabolic profile in patients with metabolic syndrome.Objective: To compare the effects of metformin and rimonabant on insulin resistance and biochemical hyperandrogenemia.Subjects: Twenty patients with PCOS and biochemical hyperandrogenemia were recruited...